Search

David A Claremon

from Yardley, PA
Age ~68
Get Report
Also known as:
David Dr Claremon, David Alan Claremon, David H Claremon, Alan David Claremon, Dave A Claremon, Claremon David Alan
Related to:
Amanda J Claremon, 50David A Brown, 52Carolyn Brown, 82Leon ClaremonIrene Brown
Connected to:
Chris S Claremont, 74Jacob J Clarenbach, 50Jennifer Clarence, 68Johnson Clarence, 48Justin L Clarence, 52Louis Clarence, 57Sushil K Clarence, 72Jose L Claret, 32Brian T Clarey, 39Charles G Clarey, 46

David Claremon Phones & Addresses

  • Yardley, PA
  • Audubon, PA
  • North Wales, PA
  • Delray Beach, FL
  • Dover AFB, DE
  • New York, NY
  • Timonium, MD
  • Ambler, PA

Resumes

Resumes

David Claremon Photo 1

President

View page
Location:
1508 Aidenn Lair Rd, Ambler, PA 19002
Industry:
Biotechnology
Work:
Vitae Pharmaceuticals since Jun 2002
VP, Chemistry
Merck & Co., Inc. 1982 - 2002
Sr. Director Med Chem
Education:
University of Pennsylvania 1977 - 1982
Ph. D. Case Western Reserve University 1973 - 1977
BA, Chemistry Jersey Academy 1969 - 1973
Skills:
Chemistry
Medicinal Chemistry
Pharmaceutical Industry
Drug Discovery
Biotechnology
Drug Development
Organic Chemistry
Technology Transfer
Life Sciences
Clinical Development
Oncology
Hplc
High Performance Liquid Chromatography
Biochemistry
Leadership
Clinical Trials
Lifesciences
Strategic Planning
David Claremon Photo 2

David Claremon

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
David Claremon
Vice President
VITAE PHARMACEUTICALS, INC
Commercial Physical Research
502 W Office Ctr Dr, Fort Washington, PA 19034
(215) 461-2000, (215) 654-1262

Publications

Us Patents

Compounds Having Cytokine Inhibitory Activity

View page
US Patent:
6350744, Feb 26, 2002
Filed:
Nov 4, 1999
Appl. No.:
09/433247
Inventors:
David A. Claremon - Maple Glen PA
Gerald S. Ponticello - Lansdale PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 31501
US Classification:
5142305, 51425203, 51425202, 514256, 514275, 51425505, 514318, 514334, 544238, 544295, 544296, 544405, 546194, 546257
Abstract:
There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.

5-Benzyl-Octahydroindole And 6-Benzyl-Decahydroquinoline Nmda/Nr2B Antagonists

View page
US Patent:
6369076, Apr 9, 2002
Filed:
Oct 25, 2000
Appl. No.:
09/696582
Inventors:
Wayne Thompson - Landsdale PA
David A. Claremon - Maple Glen PA
Peter M. Munson - Harleysville PA
Assignee:
Merck Co. Inc. - Rahway NJ
International Classification:
A61K 314709
US Classification:
514314, 514394, 514397, 514412, 514303, 514259, 546158, 546164, 546118, 5483051, 5483121, 548452, 544283
Abstract:
Novel 5-benzyl-octahydroindoles and 6-benzyl-decahydroquinolines substituted in the 1-position are effective as NMDA NR2B antagonists useful for relieving pain.

Cyclic Amidines Useful As Nmda Nr2B Antagonists

View page
US Patent:
6376530, Apr 23, 2002
Filed:
Apr 17, 2000
Appl. No.:
09/550972
Inventors:
Christopher F. Claiborne - Lansdale PA
Nigel J. Liverton - Harleysville PA
David A. Claremon - Maple Glen PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D20944
US Classification:
514416, 548454, 548471
Abstract:
The invention encompasses novel compounds of Formula I as well as a method of treating NMDA mediated diseases comprising administration to a patient in need of such treatment a non-toxic amount of a compound of Formula I effective to block the NMDA NR2B receptor sub-unit. The invention also encompasses certain pharmaceutical compositions for the treatment of NMDA mediated diseases comprising compounds of Formula I and a pharmaceutically acceptable carrier.

2-Cyclohexyl Quinazoline Nmda/Nr2B Antagonists

View page
US Patent:
6380205, Apr 30, 2002
Filed:
May 21, 2001
Appl. No.:
09/862171
Inventors:
Wayne Thompson - Lansdale PA
David A. Claremon - Maple Glen PA
Peter M. Munson - Harleysville PA
John A. McCauley - Maple Glen PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D23974
US Classification:
514259, 544287
Abstract:
4-substituted cyclohexanes substituted in the 1-position with quinazoline either directly or through a C -C alkyl, C -C alkenyl, C -C alkynyl, C -C alkoxy, amino, aminoC -C alkyl, hydroxyC -C alkyl, carbonyl, cycloC -C alkyl or aminocarbonyl chain are effective as NMDA NR2B antagonists useful for relieving pain.

Substituted Pyridones Having Cytokine Inhibitory Activity

View page
US Patent:
6403596, Jun 11, 2002
Filed:
Jun 12, 2000
Appl. No.:
09/592029
Inventors:
Nigel J. Liverton - Harleysville PA
David A. Claremon - Maple Glen PA
John W. Butcher - Telford PA
Cory R. Theberge - Portsmouth NH
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D40104
US Classification:
514256, 514275, 544331, 544333
Abstract:
There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.

8-Aza-Bicyclo[3.2.1]Octane Nmda/Nr2B Antagonists

View page
US Patent:
6432976, Aug 13, 2002
Filed:
Oct 25, 2000
Appl. No.:
09/696503
Inventors:
Wayne Thompson - Lansdale PA
David A. Claremon - Maple Glen PA
Peter M. Munson - Harleysville PA
Brian Phillips - Telford PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 3146
US Classification:
514304, 546126
Abstract:
Novel 3-substituted 8-aza-bicyclo[3. 2. 1]octanes (commonly known as âtropanesâ) substituted in the 8-position are effective as NMDA NR2B antagonists useful for relieving pain.

Iminopyrimidine Nmda Nr2B Receptor Antagonists

View page
US Patent:
6440976, Aug 27, 2002
Filed:
Jun 25, 2001
Appl. No.:
09/888694
Inventors:
David A. Claremon - Maple Glen PA
John A. McCauley - Maple Glen PA
Nigel J. Liverton - Harleysville PA
Cory R. Theberge - Dover NH
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D23942
US Classification:
514256, 514248, 514249, 51425202, 544326, 544327, 544328, 544295, 544296
Abstract:
Compounds described by the chemical structural formula or a pharmaceutically acceptable salt thereof, are useful in the treatment of pain, migraine, depression, anxiety, schizophrenia, Parkinsons disease, stroke, and in the treatment of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain.

1,4 Substituted Piperidinyl Nmda/Nr2B Antagonists

View page
US Patent:
6476041, Nov 5, 2002
Filed:
Oct 25, 2000
Appl. No.:
09/696504
Inventors:
Wayne Thompson - Lansdale PA
David A. Claremon - Maple Glen PA
Peter M. Munson - Harleysville PA
Janusz Kulagowski - Sawbridgeworth, GB
Willie Whitter - West Point PA
Ian Huscroft - Bishops Stortford, GB
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07D47300
US Classification:
51426322, 546199, 546201, 546118, 514322, 514323, 514309, 544264
Abstract:
Novel piperidinyl compounds substituted in the 1- and 4-positions are effective as NMDA NR2B antagonists useful for relieving pain.
Control profile
David A Claremon from Yardley, PA, age ~68 Get Report